Immunocompetent murine models for the study of glioblastoma immunotherapy

Taemin Oh, Shayan Fakurnejad, Eli T. Sayegh, Aaron J. Clark, Michael E. Ivan, Matthew Z. Sun, Michael Safaee, Orin Bloch, Charles D. James, Andrew T. Parsa

Research output: Contribution to journalReview article

58 Citations (Scopus)

Abstract

Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.

Original languageEnglish (US)
Article number107
JournalJournal of Translational Medicine
Volume12
Issue number1
DOIs
StatePublished - Apr 29 2014
Externally publishedYes

Fingerprint

Glioblastoma
Immunotherapy
Investigational Therapies
Tumors
Neoplasm Antigens
Immunosuppressive Agents
Glioma
Immunosuppression
Survival Rate
Animal Models
Testing
Animals
Antigens
Neoplasms
Therapeutics

Keywords

  • Animal models
  • Astrocytoma
  • Glioblastoma
  • Glioma
  • Immune response
  • Immunosuppression
  • Immunotherapy
  • Murine
  • Preclinical

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Oh, T., Fakurnejad, S., Sayegh, E. T., Clark, A. J., Ivan, M. E., Sun, M. Z., ... Parsa, A. T. (2014). Immunocompetent murine models for the study of glioblastoma immunotherapy. Journal of Translational Medicine, 12(1), [107]. https://doi.org/10.1186/1479-5876-12-107

Immunocompetent murine models for the study of glioblastoma immunotherapy. / Oh, Taemin; Fakurnejad, Shayan; Sayegh, Eli T.; Clark, Aaron J.; Ivan, Michael E.; Sun, Matthew Z.; Safaee, Michael; Bloch, Orin; James, Charles D.; Parsa, Andrew T.

In: Journal of Translational Medicine, Vol. 12, No. 1, 107, 29.04.2014.

Research output: Contribution to journalReview article

Oh, T, Fakurnejad, S, Sayegh, ET, Clark, AJ, Ivan, ME, Sun, MZ, Safaee, M, Bloch, O, James, CD & Parsa, AT 2014, 'Immunocompetent murine models for the study of glioblastoma immunotherapy', Journal of Translational Medicine, vol. 12, no. 1, 107. https://doi.org/10.1186/1479-5876-12-107
Oh, Taemin ; Fakurnejad, Shayan ; Sayegh, Eli T. ; Clark, Aaron J. ; Ivan, Michael E. ; Sun, Matthew Z. ; Safaee, Michael ; Bloch, Orin ; James, Charles D. ; Parsa, Andrew T. / Immunocompetent murine models for the study of glioblastoma immunotherapy. In: Journal of Translational Medicine. 2014 ; Vol. 12, No. 1.
@article{cc18836663fe483db5850ca0596a4bea,
title = "Immunocompetent murine models for the study of glioblastoma immunotherapy",
abstract = "Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10{\%}. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.",
keywords = "Animal models, Astrocytoma, Glioblastoma, Glioma, Immune response, Immunosuppression, Immunotherapy, Murine, Preclinical",
author = "Taemin Oh and Shayan Fakurnejad and Sayegh, {Eli T.} and Clark, {Aaron J.} and Ivan, {Michael E.} and Sun, {Matthew Z.} and Michael Safaee and Orin Bloch and James, {Charles D.} and Parsa, {Andrew T.}",
year = "2014",
month = "4",
day = "29",
doi = "10.1186/1479-5876-12-107",
language = "English (US)",
volume = "12",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Immunocompetent murine models for the study of glioblastoma immunotherapy

AU - Oh, Taemin

AU - Fakurnejad, Shayan

AU - Sayegh, Eli T.

AU - Clark, Aaron J.

AU - Ivan, Michael E.

AU - Sun, Matthew Z.

AU - Safaee, Michael

AU - Bloch, Orin

AU - James, Charles D.

AU - Parsa, Andrew T.

PY - 2014/4/29

Y1 - 2014/4/29

N2 - Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.

AB - Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in clinical outcomes are modest, in no small part due to tumor-induced immunosuppressive mechanisms that promote immune escape and immuno-resistance. Immunotherapeutic strategies aimed at bolstering the immune response while neutralizing immunosuppression will play a critical role in improving treatment outcomes for glioblastoma patients. In vivo murine models of glioma provide an invaluable resource to achieving that end, and their use is an essential part of the preclinical workup for novel therapeutics that need to be tested in animal models prior to testing experimental therapies in patients. In this article, we review five contemporary immunocompetent mouse models, GL261 (C57BL/6), GL26 (C57BL/6) CT-2A (C57BL/6), SMA-560 (VM/Dk), and 4C8 (B6D2F1), each of which offer a suitable platform for testing novel immunotherapeutic approaches.

KW - Animal models

KW - Astrocytoma

KW - Glioblastoma

KW - Glioma

KW - Immune response

KW - Immunosuppression

KW - Immunotherapy

KW - Murine

KW - Preclinical

UR - http://www.scopus.com/inward/record.url?scp=84899968056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899968056&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-12-107

DO - 10.1186/1479-5876-12-107

M3 - Review article

C2 - 24779345

AN - SCOPUS:84899968056

VL - 12

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 107

ER -